Background: Human cytomegalovirus (HCMV) infections cause significant morbidity in immunocompromised hosts. The aim of this study was to characterize the role of two HCMV DNA polymerase mutations (K805Q and T821I) found in a ganciclovir-and foscarnet-resistant clinical isolate from an AIDS patient. Methods: The effects of single and dual DNA polymerase mutations on virus susceptibility and replicative capacity, as well as on enzymatic activity, were studied using recombinant viruses generated from overlapping cosmids and DNA polymerase enzymes expressed in rabbit reticulocyte lysates. Human cytomegalovirus (HCMV) infections can cause significant morbidity in immunocompromised hosts, such as recipients of bone marrow or solid organ transplants, and AIDS patients who fail or refuse highly active antiretroviral therapy [1] [2] [3] . Three antivirals and a prodrug are currently approved for the prevention and/or treatment of systemic HCMV diseases. Despite different mechanisms of action, ganciclovir (and its prodrug valganciclovir), cidofovir and foscarnet all inhibit the HCMV DNA polymerase enzyme. Following viral and/ or cellular phosphorylation, the triphosphate form of ganciclovir and the diphosphate form of cidofovir compete with the cellular pool of dNTP for incorporation into the elongating chain of viral DNA leading to reduction of subsequent polymerization [4] [5] [6] . By contrast, the pyrophosphate analogue foscarnet directly inhibits viral DNA replication by blocking the pyrophosphate exchange reaction on HCMV DNA polymerase [7] .
Human cytomegalovirus (HCMV) infections can cause significant morbidity in immunocompromised hosts, such as recipients of bone marrow or solid organ transplants, and AIDS patients who fail or refuse highly active antiretroviral therapy [1] [2] [3] . Three antivirals and a prodrug are currently approved for the prevention and/or treatment of systemic HCMV diseases. Despite different mechanisms of action, ganciclovir (and its prodrug valganciclovir), cidofovir and foscarnet all inhibit the HCMV DNA polymerase enzyme. Following viral and/ or cellular phosphorylation, the triphosphate form of ganciclovir and the diphosphate form of cidofovir compete with the cellular pool of dNTP for incorporation into the elongating chain of viral DNA leading to reduction of subsequent polymerization [4] [5] [6] . By contrast, the pyrophosphate analogue foscarnet directly inhibits viral DNA replication by blocking the pyrophosphate exchange reaction on HCMV DNA polymerase [7] .
The widespread use of antivirals for prevention and treatment of HCMV disease has raised concerns about the emergence of drug-resistant HCMV strains among immunocompromised patients [8] [9] [10] [11] [12] . Resistance to ganciclovir is predominantly associated with alterations in the HCMV UL97 kinase and, more occasionally, with mutations in the HCMV DNA polymerase gene. Resistance to cidofovir and foscarnet is caused by mutations in the HCMV DNA polymerase gene only. Depending on their location, single DNA polymerase alterations can confer resistance to one antiviral only or to all commercially available anti-HCMV compounds [13] [14] [15] [16] . 
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Introduction
A large number of single nucleotide substitutions have been reported in conserved regions of the HCMV DNA polymerase gene from drug-resistant clinical strains. Like other herpesvirus DNA polymerase enzymes, the catalytic domain of HCMV DNA polymerase contains eight conserved regions designated I to VII and the δ-region C that partially overlaps with three conserved Exo motifs. Mutations located within Exo I motif, region IV (including Exo II), the N-terminal extremity of δ-region C (including Exo III) and region V are mostly associated with resistance to ganciclovir and cidofovir. By contrast, mutations found in the C-terminal part of δ-region C and within or next to conserved region II and VI are mostly associated with foscarnet resistance [15] . Some mutations located in conserved regions III can confer a multidrug resistance phenotype [16] [17] [18] ; however, few studies have examined the effect of multiple DNA polymerase mutations in drug-resistant clinical HCMV strains and confirmed the role of compensatory mutations that could restore viral fitness.
We undertook a detailed study of two HCMV DNA polymerase mutations in conserved region III (K805Q and T821I) found in the clinical isolate of an AIDS patient that exhibited resistance to ganciclovir and foscarnet [12] . Because the T821I mutation has been previously associated with a very high level of foscarnet resistance, whereas the K805Q mutation was shown to confer an hypersusceptible phenotype in recombinant viruses [16] , we postulated that the latter change could potentially compensate for the drug resistance mutation by allowing improved viral replication. This hypothesis was validated by performing viral replication kinetics experiments and enzymatic assays for both single and dual DNA polymerase mutants.
Methods
Cells and viruses
Human foreskin fibroblasts (HFFs) were grown and maintained in Eagle's minimal essential medium supplemented with 10% fetal bovine serum. These cells were used for propagation of recombinant viruses, susceptibility studies and yield assays. Recombinant viruses generated by overlapping cosmids were kindly provided by Tomas Cihlar (Gilead Sciences, Foster City, CA, USA) [16] . The entire UL54 gene of wild-type (WT) and mutant recombinant viruses was sequenced to confirm the absence of undesired mutations.
Susceptibility assays
Susceptibility testing of recombinant viruses was performed in 24-well plates containing HFFs using an inoculum corresponding to 40 plaque-forming units (PFU) per wells. A standard plaque reduction assay was performed to determine drug 50% inhibitory concentration (IC 50 ) values [19] . Recombinant viruses were considered resistant to an antiviral if their IC 50 values were at least 3× greater than that of the WT virus.
Replication kinetics experiments
Replication kinetics of recombinant viruses were studied using a yield assay at a multiplicity of infection (MOI) of 0.1. Briefly, HFFs were inoculated in duplicate with recombinant viruses in 12-well plates. Cell culture supernatants were collected daily from days 2-6 post-infection and then frozen at -80°C. Viral titres of cell culture supernatants were subsequently determined by plaque assays. Viral titres of recombinant viruses were compared by a paired Student's t-test using GraphPad Prism (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). Three independent yield assay experiments were performed for each WT and recombinant mutant virus.
Expression of HCMV DNA polymerase proteins
The WT enzyme was derived from AD169 (GenBank accession number X17403). The HCMV DNA polymerase coding sequence was cloned into pCITE4a (EMD BioScience, San Diego, CA, USA) using the MscI and EcoRI restriction sites to generate pCITE-WT. Mutations were introduced in the HCMV DNA polymerase gene of pCITE-WT by site-directed mutagenesis generating pCITE-K805Q, pCITE-T821I and pCITE-K805Q+T821I. The appropriate genotype was confirmed before subsequent steps. Enzymes were expressed by an in vitro coupled transcription/translation system using rabbit reticulocyte lysates (Promega BioSystems, Sunnyvale, CA, USA) as previously described [20] . The yield of each enzyme was evaluated by incorporation of [ 35 S]-methionine followed by analysis on a SDSpolyacrylamide gel. Concentrations of approximately 1 ng/ml were obtained for WT and mutant proteins and were comparable to those obtained by Tchesnokov et al. [18] .
Filter-based polymerase assays DNA polymerase activity was tested in presence of activated calf thymus DNA as previously described [18] . Labelled DNA was measured by scintillation counting and data were further analysed with GraphPad Prism. The steady-state constants K m and V max of the HCMV DNA polymerase enzymes were determined in presence of activated calf thymus and labelled 
Foscarnet-mediated inhibition of polymerase reaction
IC 50 values of WT and mutant enzymes were measured using a filter-based assay in presence of foscarnet. Nine different concentrations of foscarnet ranging from 0.01 to 25 µM for WT and K805Q mutant, 0.62 to 160 µM for K805Q/T821I mutant and 16.25 to 260 µM for T821I mutant enzymes were used for these assays. Recombinant enzymes were considered resistant to foscarnet if their IC 50 values were at least 3× greater than that of the WT enzyme.
The inhibition constant K i was determined as previously described by Tchesnokov et al. [18] . Briefly, K i values were determined for WT and mutant HCMV DNA polymerase enzymes in presence of 1 µM of [ 
Protein stability analyses
These analyses were conducted using our previous three-dimensional (3D) model of the HCMV DNA polymerase with bound DNA template [21] , which has been refined using the published crystal structure of herpes simplex virus type-1 (HSV-1) DNA polymerase [22] . The predicted change in protein stability introduced by single amino acid substitution in HCMV DNA polymerase was evaluated with the Cologne University Protein Prediction Stability Analysis Tool (CUP-SAT) [23] . Briefly, CUPSAT prediction model uses specific atom potentials and torsion angle distribution to predict the difference in free energy (∆∆G) of WT and mutant proteins. Negative and positive predicted ∆∆G values represent destabilizing and stabilizing effects on protein structure, respectively. The free energy ∆∆G value for the double mutant protein was determined by adding the ∆∆G value of each single mutant protein.
Results
Drug susceptibility of recombinant viruses
Susceptibility of recombinant viruses to ganciclovir and foscarnet was determined by plaque reduction assay. Recombinant viruses containing mutations K805Q, T821I and K805Q+T821I had 0.8-fold, 5.3-fold and 4.8-fold increases in ganciclovir IC 50 values, respectively, compared to that of the WT virus (Table 1) . Similarly, mutants K805Q, T821I and K805Q+T821I had 0.3-fold, 23.3-fold and 15.6-fold increases in foscarnet IC 50 values, respectively, compared with that of the WT virus (Table 1) . Thus, the recombinant virus containing HCMV DNA polymerase mutation K805Q was confirmed to be susceptible to ganciclovir and hypersusceptible to foscarnet. By contrast, the T821I and K805Q+T821I mutant viruses were both resistant to ganciclovir and foscarnet with the dual mutant exhibiting a lower level of drug resistance to foscarnet.
Replicative capacities of recombinant viruses
Kinetics of production of extracellular viruses were determined by inoculating HFFs with a MOI of 0.1. The progeny yield of WT and mutant viruses obtained from days 2-6 post-infection is presented in Figure 1 . With a MOI of 0.1, initial production of extracellular viruses was detected on day 2 post-infection and subsequently increased up to day 6. On day 2 postinfection, viral yield of recombinant mutant T821I was decreased by 3.5-fold, 4.3-fold and 2.6-fold compared with those of WT, K805Q and K805Q+T821I mutant viruses, respectively (P<0.05 for T821I versus WT or K805Q), whereas initial viral inoculums used for these experiments were very similar (between 2.5-3.3×10 4 PFU/ml). This difference was still significant on day 3, but was less apparent after day 4 postinfection. These results indicate that the HCMV DNA polymerase mutation T821I is associated with an initial decrease in viral fitness in vitro, whereas mutation K805Q partially restores replication capacity in the double mutant virus.
Steady-state kinetics
To investigate the specific role of mutations K805Q, T821I and K805Q+T821I on DNA polymerase activity, WT and mutant HCMV DNA polymerase enzymes were expressed by an in vitro coupled transcription/ translation system using rabbit reticulocyte lysates. Polymerase assays were performed using a filterbased method with measurement of DNA synthesis involving long heteropolymeric DNA templates of activated calf thymus. The steady-state constants K m and V max were determined following incorporation of two labelled nucleotides (dCTP and dTTP) with similar results ( Table 2 ). The V max /K m ratio was used as a measure for polymerase activity efficiency. K805Q and K805Q+T821I mutant enzymes had a decrease in V max /K m values of 2-fold to 2.5-fold compared with that of the WT enzyme. By contrast, T821I mutant enzyme had a decrease in V max /K m values of 7.1-fold to 9.1-fold compared with that of the WT enzyme. The reduction in polymerase reaction efficiency observed with T821I mutant enzyme was associated with both the highest K m and the lowest V max values when compared with other enzymes.
Inhibitory effects of foscarnet on recombinant enzymes
Foscarnet-mediated inhibition of DNA polymerase activity was also measured using a filter-based assay. The K805Q, T821I and K805Q+T821I mutant enzymes had 0.32-fold, 68.1-fold and 20.4-fold increases in foscarnet IC 50 values, respectively, compared with that of the WT enzyme (Table 3) . Thus, the HCMV DNA polymerase mutant enzyme K805Q was hypersusceptible to foscarnet, whereas mutant enzymes T821I and K805Q+T821I were resistant to this antiviral. These results are in line with drug susceptibility results obtained with recombinant viruses. K i values were determined for WT and mutant HCMV DNA polymerase enzymes in presence of 1 µM of [
3 H]-dTTP and increasing concentrations of foscarnet as well as dATP, dCTP and dGTP. The K805Q, T821I and K805Q+T821I mutant enzymes had 0.22-fold, 30.8-fold and 12-fold increases in K i values, respectively, compared to that of the WT enzyme ( Table 3) . K i values higher than that of the WT enzyme are consistent with the foscarnet-resistant phenotypes of mutant enzymes T821I and K805Q+T821I, wheras a K i value lower than that of the WT enzyme is consistent with the foscarnet hypersusceptible phenotype of mutant enzyme K805Q.
Previous studies have described the type of competition of foscarnet on WT and mutant HCMV DNA polymerases [18, 24] . To determine whether foscarnet is a non-competitive inhibitor of viral DNA polymerase with respect to the nucleotide substrate for our HCMV DNA polymerase mutants, steady-state kinetic parameters (K m , V max and K i ) were measured in presence of increasing concentrations of foscarnet. For WT and mutant HCMV DNA polymerases, no significant change in K m values was observed, wheras V max values decreased when foscarnet concentrations increased (MM et al., data not shown). As expected, these results show that foscarnet interferes with HCMV replication in a non-competitive fashion.
Thermal stability of HCMV DNA polymerases
The influence of single amino acid changes on HCMV DNA polymerase thermal stability was determined using the web tool CUPSAT. The predicted difference in energy (∆∆G value) was compared between WT and mutant enzymes. Mutation K805Q was associated with a ∆∆G value of -1.69 kcal/mol, indicating a less stable protein structure than the WT enzyme. In our 3D model of the HCMV DNA polymerase (Figure 2A ), Lys805 has a side chain hydrogen bond (NH-O type) with Ile553 carbonyl located on the palm domain ( Figure 2B ). Substitution of an amine group by an amide group, as in K805Q, eliminates the hydrogen bond and results in a decrease in thermal stability. By contrast, mutation T821I was associated with a predicted ∆∆G value of 0.94 kcal/mol reflecting a higher stability than the WT enzyme. The T821I change introduces a hydrophobic group in the side chain that favourably interacts with neighbouring hydrophobic residues Ile833, Ala834 and Ile837 on the palm domain of HCMV DNA polymerase ( Figure 2B) . Finally, the double mutant K805Q+T821I was associated with a ∆∆G value of -0.75 kcal/mol indicating a slightly less stable protein structure than WT enzyme. 
Discussion
We showed that two HCMV DNA polymerase mutations (K805Q and T821I) found in the same clinical HCMV isolate had opposite effects on drug susceptibility profiles, replicative capacities, enzymatic functions and predicted protein thermal stability when studied separately with the use of recombinant viruses/enzymes. Together, these two mutations led to a drug-resistant virus with better replication capacity than the single T821I foscarnet-resistant mutant virus, possibly resulting in increased virulence properties. The presence of compensatory mutations restoring viral fitness as confirmed in our study for mutation K805Q must be taken into account when evaluating the genotype of HCMV strains as they could modulate the effect of well known drug resistance mutations. Some HCMV DNA polymerase mutations have been previously associated with significant reduction in viral replication, whereas others have led to modest or no decrease [13, 14, 17, [25] [26] [27] . Among others, foscarnet-resistant HCMV DNA polymerase mutations T700A and V715M [25] , as well as E756D and E756K [13] , were shown to reduce the yield of progeny virus in cell culture supernatants. Of note, Chou et al. [13] showed that a recombinant virus containing mutation D301N had lower replication kinetics than the WT virus, whereas other polymerase mutations in the corresponding clinical strain appeared to compensate for such growth attenuation in yield reduction assays. This demonstrates the importance of considering the interactions between multiple DNA polymerase mutations (that is, the effect of background sequence variations) when assessing viral fitness [13] . In our study, the influence of the foscarnet hypersusceptible mutation K805Q and the foscarnetresistant mutation T821I on replicative capacities were investigated in yield assays. Mutation K805Q was shown to partially restore replicative capacity of the double mutant virus, especially between days 2-4 postinfection, as well as the efficiency of the polymerase reaction. Apart from mutation K805Q, hypersusceptibility to foscarnet has been previously reported with a recombinant virus containing the DNA polymerase mutation D413E [13] . However, to our knowledge, mutation K805Q is the first HCMV DNA polymerase mutation shown to be associated with a hypersusceptible phenotype to foscarnet and to partially improve the viral fitness of a drug-resistant mutant.
Residues Lys805 and Thr821I are located in conserved region III in the α-helix P of the finger domain of HCMV DNA polymerase, which interacts with the template and the nucleoside triphosphate based on the crystal structure of homologous bacteriophage RB69 enzyme (gp43) in complex with bound primer/template and nucleotide substrate [28] . In our study, the mutant T821I enzyme exhibited diminished nucleotide binding capacities, but these effects could be partially restored by the addition of mutation K805Q. Indeed, in nucleotide incorporation experiments, the introduction of mutation K805Q in the double mutant K805Q+T821I enzyme was associated with a V max increase of 2-2.4-fold and a K m decrease of 1.5-1.6-fold compared to those of the single T821I mutant enzyme. The polymerase activities of the single K805Q and double K805Q+T821I mutant enzymes were similar, and they were slightly less active than that of the WT enzyme. Residues Lys805 and Thr821 must therefore play an important role in enzymatic functions of HCMV DNA polymerase.
Our Table 3 . Susceptibility and inhibition constant values of recombinant WT and mutant HCMV DNA polymerases in presence of foscarnet as determined by a filter-based assay maintaining the local structures of the finger domain primarily formed by two anti-parallel α-helices [21] . Substitutions on Leu802 and Lys805 (L802M and K805Q) carried by helix P (amino acids 797-822) might disrupt the established interactions between the finger domain and the exonuclease domain, which is necessary to maintain the finger domain at a specific angle rotated toward the palm domain in the replicative mode. Also worthy of mention is that two other residues, Gln807 and Lys811, are close to the triphosphate group located at the end of the DNA molecule where extension occurs. Lys811 might play an important role in stabilizing the triphosphate group of the DNA molecule through salt bridge interactions [21] . It was hypothesized that changes at residue Lys805 could exert their effects indirectly through disturbing interactions of adjacent highly conserved residues Gln807 and/or Lys811 [18] . Indeed, residue Lys811 of HCMV polymerase is probably involved in nucleotide binding based on kinetic analyses and 3D crystal structure data [18, 22] . It is also noteworthy that Thr821 is conserved among DNA polymerases of all human herpesviruses. It appears unlikely that Thr821 directly interacts with the DNA molecule based on our HCMV DNA polymerase model (Figure 2A ) [21] . Residues Lys805 and Thr821 are located at opposite extremities of the helix P, which is part of the finger folding motif. They interact with a loop (551-554) and another α-helix (residues 834-852) located on the palm folding motif ( Figure 2B ). Based on our 3D analyses, we can speculate that perturbation in the nature of these non-bonded interactions might affect the orientation of this central helix and thus affect the connections between the finger and palm motifs. There are some limitations to our 3D model of HCMV DNA polymerase. First, it was initially based on a combination of motif search, fold recognition and structure-based sequence alignment orchestrated by the 3D-Jury metaserver between the bacteriophage RB69 and HCMV DNA polymerases [21] . Since there is low sequence identity between RB69 and HCMV DNA polymerases, our model was refined using the published crystal structure of HSV-1 DNA polymerases [22] , as no crystal structure for HCMV DNA polymerase is yet available. The structural homology of the helix P between HSV-1 and HCMV DNA polymerases is relatively high. Furthermore, the HSV-1 DNA polymerase mutation K805Q was previously shown to be associated with foscarnet hypersusceptibility [29] and the HSV-1 mutation T821M (instead of T821I) with foscarnet and acyclovir resistance [30] . Of note, intracerebral inoculation of the HSV-1 T821M DNA polymerase mutant virus in adult mice resulted in no significant reduction in neurovirulence compared with the WT HSV-1 KOS strain [30] .
Unfortunately, no good HCMV animal model is available to evaluate the influence of various HCMV mutations on pathogenicity and virulence. For now, in vitro studies based on plaque reduction assays, reporter assays, viral yields and enzymatic activities are the only methods available to characterize the phenotype of drug-resistant HCMV DNA polymerase mutants. Viruses with defective replicative capacities might influence phenotypic assays by causing a delay in the appearance of viral plaques leading to misinterpretation of drug susceptibility results. Our work also emphasizes the importance of considering the original viral background (with possible compensatory mutations) when interpreting genotypic results from a clinical HCMV strain. In conclusion, characterization of various HCMV DNA polymerase mutants with regard to drug susceptibility, as well as replicative capacity and enzymatic activity is of prime importance to uncover the presence of other compensatory mutations, such as K805Q, in drug-resistant clinical isolates.
